Please login to the form below

Not currently logged in
Email:
Password:

Lusduna

This page shows the latest Lusduna news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck & Co's Lantus biosimilar

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lusduna (insulin glargine) for the treatment of diabetes mellitus, after it showed comparable quality, safety and ... Lusduna is now one step closer to European

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐ on biologic.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics